FDA 483 - Robinson Pharma Inc - September 25, 2014

Robinson Pharma Inc. in Santa Ana, CA, a dietary supplement manufacturer, was cited for significant quality control deficiencies during an FDA inspection. Observations included failing to ensure finished product conformity to specifications, inadequate documentation for product testing, and releasing batches for distribution without proper approval. These issues indicate a lack of robust quality control over product release and specification verification.